{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009910","form_type":"8-K","ticker":"ATEC","cik":"0001350653","company_name":"Alphatec Holdings, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.903163+00:00","generated_at":"2026-05-16T10:48:15.224065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ATEC prelim FY2025 rev ~$764M (+25%), FY2026 outlook $890M; acquires OsteoAdapt distribution rights","bullets":["Preliminary FY2025 total revenue ~$764M (25% growth); surgical revenue grew 26% with volume up 24%.","FY2025 adjusted EBITDA reaffirmed at $91M; cash balance ~$161M; Q4 free cash flow expected $6-8M.","FY2026 outlook: total revenue $890M (17% growth), adjusted EBITDA ~$130M, positive free cash flow ~$20M.","Acquired exclusive U.S. distribution rights for Theradaptive's OsteoAdapt (rhBMP-2 biologic, Phase II for spinal fusion)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009910","json":"https://secwatch.observer/filing/0001193125-26-009910.json","markdown":"https://secwatch.observer/filing/0001193125-26-009910.md","text":"https://secwatch.observer/filing/0001193125-26-009910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1350653/000119312526009910/0001193125-26-009910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1350653/000119312526009910/atec-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:48:15.224065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}